By studying the ternary complex formation of VHL/753B and BCL2 or BCL-XL, it was possible to optimize the linker design and improve potency for both BCL-XL and BCL2 degradation, resulting in a highly promising compound that exhibited enhanced activity in leukemia cells.425. This evidence concerns the gene BCL2L1 and leukemia.